Term
|
Definition
| leukocyte common antigen, differentially expressed during maturation of stem cells to HSCs |
|
|
Term
|
Definition
| predominant form, rearranges first |
|
|
Term
|
Definition
|
|
Term
|
Definition
| mutated in Polycythemia Vera, Essential Thrombocytosis, Myelofibrosis |
|
|
Term
|
Definition
| common acute leukemia antigen (ALL) |
|
|
Term
| Osteoclast Activating Factor |
|
Definition
| causes lytic bone lesions (multiple myeloma) |
|
|
Term
| Transthyretin/B2microglobulin/AA |
|
Definition
| proteins commonly causing amyloidosis |
|
|
Term
|
Definition
| markers on Reed-Sternberg cells (Hodgkin's) |
|
|
Term
|
Definition
| markers for Bcells (follicular lymphoma, Burkitt lymphoma) |
|
|
Term
|
Definition
| markers for B-cells (DLBCL, marginal zone lymphoma) |
|
|
Term
|
Definition
| causes proliferation (burkitt lymphoma) |
|
|
Term
|
Definition
| markers for Bcells (mantle cell lymphoma) |
|
|
Term
|
Definition
| markers for Bcells (small lymphocytic lymphoma) |
|
|
Term
|
Definition
| marker for Tcells/NKcells (mycosis fungoides) |
|
|
Term
|
Definition
| converts monocytes to dendritic cells |
|
|
Term
|
Definition
| activates dendritic cells |
|
|
Term
|
Definition
| marker for histiocytic sarcoma/lymphoma |
|
|
Term
|
Definition
| markers for histiocytosis X |
|
|
Term
|
Definition
| mutated in Mast Cell Infiltrates |
|
|
Term
|
Definition
| marker of Bcells, target of rituximab, essential for EBV infection |
|
|
Term
|
Definition
| marker on Tcells, elevated in EBV mononucleosis |
|
|
Term
|
Definition
| cleaves factor Va/VIIa, complete deficiency is fatal, partial deficiency causes coumadin-induced skin necrosis/recurrent venous thrombosis, vitamin K dependent, infused for survival of septic shock |
|
|
Term
|
Definition
|
|
Term
|
Definition
| vitamin K-dependent factors |
|
|
Term
|
Definition
| carried in plasma complexed with vWF |
|
|
Term
|
Definition
| adheres to exposed ECM around vessels, binds gpIb, synthesized in endothelium/megakaryocytes, stored in platelets, complexed with Factor VIII, cleaved to p176/p140 |
|
|
Term
|
Definition
| causes platelets to adhere to each other |
|
|
Term
|
Definition
| irreversibly binds thrombin and other protease factors |
|
|
Term
|
Definition
| combines with heparin, resulting antigen responsible for HIT |
|
|
Term
| rifampin/barbituates/phenytoin/alcohol |
|
Definition
| induce CYP450, decrease effectiveness of warfarin |
|
|
Term
|
Definition
| mutated C677T or A1289C in hyperhomocystinemia |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| sets rate (accumulation/elimination) of warfarin response |
|
|
Term
|
Definition
| set amount (concentration) of warfarin response, variants require decreased dosage |
|
|
Term
|
Definition
| rapid warfarin metabolizers, 5mg/day |
|
|
Term
|
Definition
| intermediate warfarin metabolizer (2.5-2.7mg/day) |
|
|
Term
|
Definition
| poor warfarin metabolizers, 1.5-1.7mg/day |
|
|
Term
|
Definition
| involved in both steps of clopidogrel conversion |
|
|
Term
|
Definition
| extensive clopidogrel metabolizers |
|
|
Term
|
Definition
| intermediate clopidogrel metabolizers |
|
|
Term
|
Definition
| poor clopidogrel metabolizers |
|
|
Term
|
Definition
| ultrarapid clopidogrel metabolizers |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| C806T/C3402T, increased translation |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| stops tPa, from endothelial smooth muscle |
|
|
Term
|
Definition
| stops tPa, from endothelial smooth muscle |
|
|
Term
|
Definition
| cofactor for Protein C, vitamin K dependent, bound and free forms, decreased during pregnancy |
|
|
Term
|
Definition
| activates thrombin, set up by Factor Va |
|
|
